1.Shanghai yakatanga mishonga yechivanhu yekuChina patent uye magadzirirwo ari nyore uye asiri emishonga kurapwa kubatsira vanhu kurwisa furuwenza.
Shanghai Municipal Administration yeTraditional Chinese Medicine yakaratidza musi wa5 kuti National Base for the Prevention and Control of Chinese Medicine Epidemic Diseases (Shanghai) yakatungamira mukugadzira Chinese Medicine Prevention and Control Plan ye2023 Spring Influenza muShanghai (Muedzo) (pano yakazonzi chirongwa), yakaronga kunzwisiswa kwemushonga weChinese pafuruwenza, yakagadzira mishonga yekuChina yevakuru nevana zvichibva pakusiyana kwechirwere, uye yakatanga mishonga yakawanda yechinyakare yeChinese patent uye magadzirirwo ari nyore uye asiri emishonga ekurapa furuwenza uye kudzora. .
Munguva yechando uye muchirimo, mamiriro ekunze anodziya uye anotonhora, tembiricha musiyano pakati pemasikati neusiku uri kuchinjika, uye mwaka nemwaka zvirwere zvinotapukira zvakapinda muchiitiko chepamusoro uye nguva yedenda.Munguva pfupi yapfuura, nhamba yevarwere vane furuwenza A uye zvimwe zvirwere zvakagamuchirwa nezvipatara zvikuru muShanghai yakawedzera.Chirongwa ichi chine chinangwa chekupa kutamba kwakazara kune hunhu uye zvakanakira zvechivanhu Chinese mushonga mukudzivirira uye kurapwa kwefuruwenza.
Zhang Wei, mumwe wevanyori vechirongwa ichi, mutevedzeri wemutungamiri weCCIDID-19 Nyanzvi Boka reTraditional Chinese Medicine Kurapa uye director wePulmonary Disease department reShuguang Hospital, anotenda kuti kukura kwefuruwenza (furuwenza) kunonyanya kuzvimiririra. limiting.Vamwe vana vasina simba uye vanhu vakura vane zvirwere zvepasi vanogona kukonzera mamwe matambudziko nekuda kwezvirwere zvekunze, inova inotarisisa yekudzivirira uye kurapwa kwechivanhu Chinese mushonga uye kumadokero mushonga.Akaudza vatori venhau kuti mishonga yechivanhu yekuChina inotenda kuti furuwenza ndeyechikamu chezvinotonhora.Zvinoenderana nekunzwisisa kwechinyakare, kuongororwa uye kurapwa kunonyanya kuenderana neiyo syndrome yekusiyanisa system uye nzira dzekurapa dzevatanhatu meridians, iyo syndrome musiyano weWeiqi uye Yingxue, uye iyo syndrome yekusiyanisa hurongwa uye nzira yekurapa yejiao matatu, uye kutarisisa. inobhadharwa kune yakasanganiswa kushandiswa kwekusimbisa uye kubvisa pathogenic zvinhu nematanho nematanho.
"Furuwenza inonyanya kuzvidzivirira uye inogona kurapwa munguva pfupi mushure mekurapwa kwezviratidzo uye kupindira kweTCM."Zhang Wei akataura kuti, pamusoro pemishonga yechinyakare yeChinese patent uye gadziriro dziri nyore dzinokurudzirwa muchirongwa ichi, zvipatara zvikuru zveTCM muShanghai zvine ruzivo rwakapfuma mukuongororwa uye kurapwa kwefuruwenza, pamwe nekutevedzana kwegadziriro dzechipatara nemirairo.
Zvinonzi kutapurirana kwazvino kunonyanya kuve H1N1.Kana ichienzaniswa nedzihwa, inotapuriranwa zvakanyanya, ine fivha yakanyanya uye inogara kwenguva refu, ine zviratidzo zvehurongwa huri pachena, uye ine chirwere chakareba.
Xue Zheng, munyori weChirongwa cheVana uye director weDhipatimendi rePediatrics reShanghai Municipal Hospital yeTraditional Chinese Medicine, anotenda kuti vana vari pasi pemakore mashanu ekuberekwa vanogona kubatwa nefuruwenza.Vana vanobatwa nefuruwenza uye vane zviratidzo zvakakomba nekuda kwemapapu avo asina kusimba.Mushonga wechiChinese wechinyakare unobata basa rakanaka kwazvo mukudzivirira uye kurapwa kwefuruwenza muvana, kunyanya mukurapa furuwenza A, iyo inogona kutadzisa kupararira nekudzika kwehutachiona, nekukurumidza kunatsiridza zviratidzo, uye ine yakakura spectrum.Pediatrics muzvipatara zvikuru zveChinese neWestern zvakare vane gadziriro dzechipatara dzakakura dzinoshandiswa zvakanyanya mumakiriniki.
Urongwa uhwu hwakagadzira chibvumirano chemushonga wechinyakare chekuChina uye mishonga yechinyakare yeChinese patent uye gadziriro iri nyore yekurapa furuwenza yevana, uye yakapa zano nzira dzakareruka uye dzisingadhure dzekunze dzekurapa kwechinyakare Chinese mushonga.Vabereki vanogona kuita zvechinyakare Chinese mushonga kupindira kuburikidza nekunze nzira dzekurapa senge dietotherapy, masaja, nzeve dzenzeve, kushandisa uye rusenzi pendant kurapa kubatsira vana kuvandudza zviratidzo nekukurumidza uye kupora hutano nekukurumidza.
2.Vatsvakurudzi veScientific vakawana mutsara we anti-hepatoma active ingredients kubva kumushonga weArtemisia annua.
Kunming Institute of Botany, Chinese Academy of Sciences, yakazivisa musi wa21 kuti timu yekutsvagisa yaChen Jijun yakawana akatevedzana sesquiterpene dimers ane anti-cancer yechiropa chiitiko kubva kumushonga chirimwa Artemisia scoparia.Mhedzisiro yetsvakiridzo yakakodzera ichangobva kuburitswa mupepanhau rine mukurumbira pasi rose Signal Transmission uye Targeted Therapy.
Gomarara rechiropa ibundu rakashata rinokanganisa zvakanyanya hutano hwevanhu.Gore rega rega, nhamba yezviitiko zvitsva zvegomarara rechiropa munyika inodarika 840000, uye nhamba yenzufu dzinokonzerwa nekenza yechiropa dzinosvika 780000, nepo 50% yezviitiko zvitsva zvichiitika muChina.Parizvino, kune ina tyrosine kinase inhibitors, sorafenib, regafinil, lovatinib uye cabotinib, imwe yevascular endothelial growth factor receptor 2 antagonist, ramolumab, uye maviri PD-1 inhibitors, navumab uye pamuzumab, iyo inoshandiswa mukurapa kwechirwere chechiropa. , asi maumbirwo acho ari nyore uye ari nyore kugadzira kusaramba kwezvinodhaka.
Mumakore achangopfuura, boka rekutsvakurudza raChen Jijun rakazvipira kutsvaga anti-hepatoma lead compounds uye mishonga inovandudza ine chimiro chakasiyana uye nzira itsva yekuita kubva kuArtemisia miti, uye yakabudirira kugadzira nzira yekuparadzanisa inobatanidza kubvuma kwekutungamira kwe sesquiterpene dimers muArtemisia. zvirimwa zvine kuteedzera kweanti-hepatoma chiitiko.Ichi chidzidzo chakawana kekutanga kuti chidimbu cheArtemisia annua chine inhibitory yakasimba pamasero matatu ehepatoma, uye kekutanga, 36 novel sesquiterpene dimers ye9 structural types - Artemisia annua A1-A3, B1-B2, C1-C4 , D, E, F1-F15, G1-G8, H uye ini takanga taparadzaniswa nechikamu chinoshanda cheArtemisia annua.
Zvimwe zvidzidzo zvakaratidza kuti pakati pe 36 novel sesquiterpene dimers, basa re artemisinin G5 uye G7 rakanga rakanakisisa, iro rakanga rakaenzana nekutanga-mutsara wekiriniki anti-hepatoma drug sorafenib;Mukuwedzera, maodzanyemba artemisinin G7 yakaratidza zviri nani kusarudza uye kuchengeteka kupfuura sorafenib yeTHLE-2 mumasero echiropa;Panguva imwecheteyo, kumaodzanyemba artemisinin G7 inogonawo kudzivisa kupararira kwemasero eHepG2 nekudzivisa kupinda uye kutama kwemasero ehepatoma, zvichiita kuti apoptosis uye kuvhara G2 / M cell cycle.
Ichi chidzidzo chakaratidza kekutanga nhevedzano ye sesquiterpene dimers ine novel skeleton uye akasiyana dhizaini muArtemisia annua, yakapfumisa marudzi ezvimiro zve sesquiterpene dimers muArtemisia zvidyarwa, uye yakapa akasiyana-siyana evamiriri mamorekuru uye yakakosha pharmacological hwaro hwekutsvagisa kweanti anti. -hepatoma mishonga.
Kusvika pari zvino, timu yaChen Jijun yekutsvagisa yakazvitsaura uye yaona zana nemakumi maviri nemaviri novel sesquiterpenoid dimers ine anti-hepatoma chiitiko kubva kuArtemisia australis, Artemisia sinica, Artemisia medinalis, Artemisia cowtail naArtemisia Mongolica, inoverengera makumi mashanu neshanu muzana ehuwandu hwemakumi maviri nemazana mana emakumi maviri nenhatu. Artemisia zvinomera munyika.
JinDun Medicaline yenguva refu yekutsvagisa kwesainzi kushandira pamwe uye tekinoroji kubatanidza nemayunivhesiti eChinese.Nezviwanikwa zvekurapa zveJiangsu zvakapfuma, ine hukama hwekutengesa kwenguva refu neIndia, Southeast Asia, South Korea, Japan nemimwe misika.Inopawo musika uye masevhisi ekutengesa mukuita kwese kubva pakati kusvika pakupera chigadzirwa API.Shandisa zvakaunganidzwa zviwanikwa zveYangshi Chemical mune fluorine chemistry kupa akakosha makemikari ekugadzirisa masevhisi kune vanobatana.Ipa maitiro ekuvandudza uye kusachena kwekutsvaga masevhisi kune kunanga vatengi.
JinDun Medical inoomerera pakugadzira timu ine zviroto, kugadzira zvigadzirwa zvine rukudzo, zvine hungwaru, zvine hungwaru, uye kuenda zvese kunze kuti ive shamwari yakavimbika uye shamwari yevatengi! One stop solution vanopa, yakagadziridzwa R&D uye customized kugadzirwa masevhisi emishonga vepakati uye APIs, professionalcustomized pharmaceutical production(CMO) uye yakasarudzika mishonga yeR&D uye kugadzira (CDMO) vanopa masevhisi.
Nguva yekutumira: Mar-30-2023